merck and endocyte in 1 billion drug deal
Last Updated : GMT 06:49:16
Arab Today, arab today
Arab Today, arab today
Last Updated : GMT 06:49:16
Arab Today, arab today

Merck and Endocyte in $1 billion drug deal

Arab Today, arab today

Arab Today, arab today Merck and Endocyte in $1 billion drug deal

Washington - Arabstoday

Merck & Co Inc said it acquired the development and marketing rights to Endocyte Inc’s experimental cancer drug for $120 million in cash and up to $880 million in milestone payments. According to the deal, Endocyte will be responsible for majority of funding and completion of the ovarian cancer trial. It will receive an equal share of profits in the United States, if the drug is approved. Merck, through a subsidiary, will gain worldwide rights to commercialise the drug vintafolide. Vintafolide is currently being tested in a late-stage trial for ovarian cancer and a mid-stage trial for non-small cell lung cancer. Endocyte had planned to file for marketing approval for the drug in the third quarter of 2012. Vintafolide was granted an orphan drug status in Europe last month. “Vintafolide is a promising and innovative late-stage cancer drug candidate. In addition to pursuing the lead indication of platinum-resistant ovarian cancer, Merck plans to further evaluate its potential for treatment of multiple other cancer types,” said Peter S. Kim, executive vice president and president Merck Research Laboratories. “This agreement underscores our strategy of building a portfolio of oncology therapeutics that employ a companion diagnostic to facilitate selection of those patients most likely to respond to treatment.” Under the agreement, Merck, through a subsidiary, will gain worldwide rights to develop and commercialise vintafolide. Endocyte will receive a $120 million upfront payment and is eligible for milestone payments of up to $880 million based on the successful achievement of development, regulatory and commercialization goals for vintafolide for a total of six cancer indications.

arabstoday
arabstoday

Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

merck and endocyte in 1 billion drug deal merck and endocyte in 1 billion drug deal

 



Name *

E-mail *

Comment Title*

Comment *

: Characters Left

Mandatory *

Terms of use

Publishing Terms: Not to offend the author, or to persons or sanctities or attacking religions or divine self. And stay away from sectarian and racial incitement and insults.

I agree with the Terms of Use

Security Code*

merck and endocyte in 1 billion drug deal merck and endocyte in 1 billion drug deal

 



GMT 15:28 2017 Tuesday ,17 October

Tunisia economic growth picks up in first quarter

GMT 22:57 2017 Saturday ,23 December

Saif bin Zayed attends wedding ceremony in Al Ain

GMT 14:01 2013 Saturday ,20 April

Iran sees no need for OPEC emergency prices meeting

GMT 08:58 2017 Wednesday ,05 April

North Korea fires missile into Sea of Japan

GMT 07:17 2016 Friday ,15 January

'Harry Potter' star Alan Rickman dies aged 69

GMT 14:43 2015 Saturday ,26 December

Nazaha head arrives in Cairo
Arab Today, arab today
 
 Arab Today Facebook,arab today facebook  Arab Today Twitter,arab today twitter Arab Today Rss,arab today rss  Arab Today Youtube,arab today youtube  Arab Today Youtube,arab today youtube

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©

arabstoday arabstoday arabstoday arabstoday
arabstoday arabstoday arabstoday
arabstoday
بناية النخيل - رأس النبع _ خلف السفارة الفرنسية _بيروت - لبنان
arabstoday, Arabstoday, Arabstoday